Mechanism of epimedium and its active components in treating liver cancer based on network pharmacology and in vitro experiment

LI Yuan; YANG Yin-li; JIANG Zhan-sheng; PAN Zhan-yu

doi:10.16025/j.1674-1307.2023.11.013

您当前的位置：

首页 >

文章列表页 >

Mechanism of epimedium and its active components in treating liver cancer based on network pharmacology and in vitro experiment

更新时间：2023-12-25

- Mechanism of epimedium and its active components in treating liver cancer based on network pharmacology and in vitro experiment
- Beijing Journal of Traditional Chinese Medicine Vol. 42, Issue 11, Pages: 1225-1233(2023)
- 作者机构：
  
  1.天津中医药大学，天津 301617
  2.天津医科大学肿瘤医院国家肿瘤临床医学研究中心天津市“肿瘤防治”重点实验室天津市恶性肿瘤临床医学研究中心，天津 300181
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2023.11.013
  CLC：
扫描看全文
李圆，杨银莉，姜战胜，等.基于网络药理学及体外实验探讨淫羊藿及其活性成分治疗肝癌的作用机制［J］.北京中医药，2023，42（11）：1225-1233.

LI Yuan,YANG Yin-li,JIANG Zhan-sheng,et al.Mechanism of epimedium and its active components in treating liver cancer based on network pharmacology and in vitro experiment[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(11):1225-1233.
李圆，杨银莉，姜战胜，等.基于网络药理学及体外实验探讨淫羊藿及其活性成分治疗肝癌的作用机制［J］.北京中医药，2023，42（11）：1225-1233. DOI： 10.16025/j.1674-1307.2023.11.013.

LI Yuan,YANG Yin-li,JIANG Zhan-sheng,et al.Mechanism of epimedium and its active components in treating liver cancer based on network pharmacology and in vitro experiment[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(11):1225-1233. DOI： 10.16025/j.1674-1307.2023.11.013.

摘要

目的,2,通过网络药理学、分子对接技术和体外实验验证研究淫羊藿及其活性成分治疗肝癌的作用机制。,方法,2,通过中药系统药理学分析平台（TCMSP）筛选淫羊藿的活性成分和作用靶点，利用GeneCards、DrugBank等5个数据库筛选肝癌相关靶点。筛选二者共同的潜在功能靶位，运用Cytoscape 3.9.0软件构建肝癌-淫羊藿活性成分-靶点网络图，使用R语言进行基因本体（GO）功能及京都基因与基因组百科全书（KEGG）通路富集分析。结合 STRING 数据库和Cytoscape 3.9.0对交集靶点构建蛋白质-蛋白质相互作用（PPI）网络，筛选核心靶点。运用 AutoDock、Vina和 PyMOL 软件对淫羊藿关键成分与核心靶点进行分子对接验证。最后通过体外细胞实验验证网络药理学结果。,结果,2,分析获得19 个淫羊藿主要活性成分，淫羊藿与肝癌共同靶点139 个，靶点经富集分析得到2 347个GO生物学功能和171条信号通路；分子对接结果显示核心成分与关键靶点均有较高的结合能力。体外实验结果表明核心成分淫羊藿素能显著抑制肝癌细胞系MHCC97H和MHCC97L的增殖，并抑制Bcl-2凋亡调节因子（Bcl-2）和细胞周期蛋白D1（cyclin D1）的表达，增强Bcl-2相关X因子（Bax）的表达。此外，淫羊藿素可能通过抑制细胞外信号调节激酶1/2（ERK1/2）和p38丝裂原活化蛋白激酶（p38 MAPK）信号通路发挥抗肿瘤作用。,结论,2,淫羊藿及其主要成分淫羊藿素等可能通过多靶点、多通路调控肝癌细胞生长和分化，调节细胞凋亡等应激反应，实现对肝癌的治疗作用。

Abstract

关键词

淫羊藿肝癌网络药理学淫羊藿素

Keywords

references

BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.

王涛, 陈东风. 肝细胞癌的临床诊治:从指南到临床实践[J]. 临床肝胆病杂志,2021,37(8):1745-1747.

CLARK T, MAXIMIN S, MEIER J, et al. Hepatocellular carcinoma: Review of epidemiology, screening, imaging diagnosis, response assessment, and treatment[J]. Curr Probl Diagn Radiol, 2015,44(6):479-486.

LING CQ, FAN J, LIN HS, et al. Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine[J]. J Integr Med, 2018,16(4):236-248.

刘谊民, 张黄琴, 刘玉萍,等. 淫羊藿抗肝癌活性成分及作用机制研究进展[J]. 中国实验方剂学杂志,2022,28(17):217-225.

RU J, LI P, WANG J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform, 2014,6:13.

FAN J, DE LANNOY IA. Pharmacokinetics[J]. Biochem Pharmacol, 2014,87(1):93-120.

UniProt Consortium. UniProt: the universal protein knowledgebase in 2021[J]. Nucleic Acids Res, 2021,49(D1):D480-D489.

王伟芹, 高占华, 尹常健. 中医药治疗原发性肝癌的方法学研究[J]. 临床肝胆病杂志,2021,37(9):2009-2015.

赵文霞, 陈欣菊. 原发性肝癌中医药诊疗原则及方案构建[J]. 临床肝胆病杂志,2021,37(9):2005-2008.

LAM P, CHEUNG F, TAN HY, et al. Hepatoprotective effects of chinese medicinal herbs: A focus on anti-inflammatory and anti-oxidative activities[J]. Int J Mol Sci, 2016,17(4):465.

DAI W, GAO Q, QIU J, et al. Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma[J]. Tumour Biol, 2016,37(5):6307-6313.

郑岩松, 雷文俤, 陈明流,等. 槲皮素抑制TGF-β1诱导SMMC-7721人肝癌细胞发生EMT的效果研究[J]. 毒理学杂志,2019,33(6):465-468.

XIAO X, HU Q, DENG X, et al. Old wine in new bottles: Kaempferol is a promising agent for treating the trilogy of liver diseases[J]. Pharmacol Res, 2022,175:106005.

YANG Y, ZHENG J, WANG M, et al. NQO1 promotes an aggressive phenotype in hepatocellular carcinoma via amplifying ERK-NRF2 signaling[J]. Cancer Sci, 2021,112(2):641-654.

LI J, HUANG Q, LONG X, et al. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways[J]. J Hepatol, 2015,63(6):1378-1389.

XIANG DM, SUN W, ZHOU T, et al. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance[J]. Gut, 2019,68(10):1858-1871.

农宜熙, 黄俊玲, 黄赞松,等. 人肝癌细胞株的特性及其实验应用[J]. 世界华人消化杂志,2017,25(2):159-165.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application of GUAN You-bo's “Zhongzhou Theory” in the treatment of liver cancer

Related Author

No data

Related Institution

首都医科大学附属北京中医医院肝病科

北京中医药大学

首都医科大学

⁰